WBB Securities upgraded shares of Vogenx (NASDAQ:VOGX – Free Report) to a moderate buy rating in a research note published on Wednesday, Marketbeat reports.
A number of other brokerages have also recently issued reports on VOGX. JonesTrading began coverage on Vogenx in a report on Tuesday. They set a “buy” rating and a $55.00 price objective on the stock. Wall Street Zen raised shares of Vogenx to a “hold” rating in a research note on Saturday, August 22nd. One analyst has rated the stock with a Strong Buy rating and one has issued a Buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Strong Buy” and a consensus price target of $48.50.
Check Out Our Latest Stock Report on Vogenx
Vogenx Stock Performance
About Vogenx
Vogenx Inc is a clinical-stage biopharmaceutical company. It focused on the discovery and development of novel therapeutics for the treatment of serious diseases associated with dysfunctions in human metabolism, including PBH and gastroparesis. The company’s product candidate includes mizagliflozin, is an orally administered, minimally absorbed small molecule drug candidate in development for the treatment of PBH, gastroparesis, and GIP-dependent Cushing’s Syndrome. Vogenx Inc is based in RALEIGH, NC.
Further Reading
- Five stocks we like better than Vogenx
- The Path to $230 Billion: Broadcom Outlines the Next Phase of Its AI Growth Story
- NVIDIA’s Hugging Face Deal Raises a Bigger Question About Its AI Moat Now
- Dropping the Dough: Yum! Brands Strategically Trims the Fat
- These 3 Stock Charts Just Flashed the Dreaded Death Cross Pattern
Receive News & Ratings for Vogenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vogenx and related companies with MarketBeat.com's FREE daily email newsletter.
